Halozyme sues Merck; FDA blames cuts for Vanda delay

Halozyme sues Merck; FDA blames cuts for Vanda delay

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an FDA rejection dragged on, while Sanofi revealed an immune drug setback.

Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual property.

Halozyme Sues Merck; FDA Blames Cuts For Vanda Delay - Data Intelligence

Today, a brief rundown of news involving Merck and Vanda Pharmaceuticals, as well as updates from Sanofi and Novo Holdings that you may have missed. Halozyme Therapeutics has sued Merck & Co., alleging that the pharmaceutical company is infringing on multiple patents in developing a subcutaneous form of the cancer immunotherapy Keytruda. Halozyme has a drug delivery technology that can turn intravenously infused medicines into under-the-skin inj…